Total Funding
24
50
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
81031
Developing a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology.
- Margaret Brimble: Founder
Baiju R. Shah: ChairmanPast Role: BioMotiv, CEO
About the Company
SapVax is advancing discoveries made by researchers from the University of Auckland in New Zealand. Their academic founders have developed a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines. The Sapvax team is developing a pipeline of products for the
treatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.
Women Founded
